Cronos Australia Ltd. (AU:VIT)
ASX:VIT
VIT Stock Chart & Stats
AU$0.06
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.06
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.08
Previous CloseN/A
Volume1.00K
Average Volume (3M)228.84K
Market Cap
AU$25.18M
Enterprise ValueAU$36.43M
Total Cash (Recent Filing)AU$6.10M
Total Debt (Recent Filing)AU$17.34M
Price to Earnings (P/E)―
Beta1.87
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.28%
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding662,741,800
10 Day Avg. Volume238,134
30 Day Avg. Volume228,844
Financial Highlights & Ratios
PEG Ratio-1.01
Price to Book (P/B)0.78
Price to Sales (P/S)0.30
P/FCF Ratio14.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance-sheet ConservatismLow leverage and a high equity ratio give Cronos Australia durable financial flexibility. A conservative capital structure reduces refinancing and interest risks, supporting multi-quarter resilience for R&D, regulatory timelines, or working-capital needs without forcing distress asset sales.
Gross Margin StabilityA ~27% gross margin in specialty/generic drugs indicates an ability to cover direct production costs and preserve pricing or manufacturing efficiency. This margin base supports longer-term operating leverage if revenues recover, helping protect profitability versus lower-margin peers.
Strong FCF-to-income ConversionConverting nearly all net income into free cash historically shows the company can produce cash when earnings are positive. That structural ability supports dividend capacity and capex funding when operational headwinds ease, enhancing medium-term capital allocation choices.
Bears Say
Revenue DeclineDeclining top-line indicates demand, pricing, or product-mix headwinds. Sustained revenue erosion reduces scale, compresses fixed-cost absorption, and limits ability to fund R&D or marketing internally, challenging growth prospects over the next several quarters without strategic changes.
Collapse In Free Cash Flow GrowthAn extreme drop in FCF growth signals material cash outflows or operating deterioration. This materially weakens liquidity and constrains discretionary spending, capital returns, or investment, creating a sustained funding and execution risk until cash generation normalizes.
Weak Operating Cash ConversionVery low operating cash conversion implies earnings are not translating into cash, pointing to working-capital stress or non-cash accounting gains. This undermines earnings quality and increases reliance on the balance sheet, limiting durability of dividends or reinvestment plans.
Cronos Australia Ltd. News
VIT FAQ
What was Cronos Australia Ltd.’s price range in the past 12 months?
Cronos Australia Ltd. lowest share price was AU$0.04 and its highest was AU$0.08 in the past 12 months.
What is Cronos Australia Ltd.’s market cap?
Cronos Australia Ltd.’s market cap is AU$25.18M.
When is Cronos Australia Ltd.’s upcoming earnings report date?
Cronos Australia Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 154 days.
How were Cronos Australia Ltd.’s earnings last quarter?
Cronos Australia Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.001.
Is Cronos Australia Ltd. overvalued?
According to Wall Street analysts Cronos Australia Ltd.’s price is currently Overvalued.
Does Cronos Australia Ltd. pay dividends?
Cronos Australia Ltd. pays a Annually dividend of AU$0.002 which represents an annual dividend yield of 3.28%. See more information on Cronos Australia Ltd. dividends here
What is Cronos Australia Ltd.’s EPS estimate?
Cronos Australia Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cronos Australia Ltd. have?
Cronos Australia Ltd. has 662,741,800 shares outstanding.
What happened to Cronos Australia Ltd.’s price movement after its last earnings report?
Cronos Australia Ltd. reported an EPS of -AU$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.167%.
Which hedge fund is a major shareholder of Cronos Australia Ltd.?
Currently, no hedge funds are holding shares in AU:VIT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cronos Australia Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:VIT Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.51%
12-Months-Change
Fundamentals
Return on Equity
7.64%
Trailing 12-Months
Asset Growth
5.91%
Trailing 12-Months
Company Description
Cronos Australia Ltd.
Vitura Health Limited engages in the sale and distribution of medicinal cannabis products in Australia and Asia. Its brands include CanView, Burleigh Heads Cannabis, CDA Clinics, Cannadoc, and Adaya. The company was formerly known as Cronos Australia Limited and changed its name to Vitura Health Limited in February 2023. The company was incorporated in 2018 and is based in South Yarra, Australia.
Technical Analysis
Elixinol Wellness
―
Cann Group
―
Epsilon Healthcare Limited
―
Little Green Pharma Ltd.
―
―